低分子肝素治疗胎儿生长受限的护理干预

目的 探讨低分子肝素治疗胎儿生长受限的临床效果以及护理措施.方法 选择我院2010年3月～2012年3月间出现胎儿生长受限的72例妊娠妇女,患者入院后皮下注射5000U/d低分子肝素治疗,并选取我院同期胎儿生长受限的72例妊娠妇女接受基础治疗作为对照组.结果 实验组治疗后平均宫高增量及胎儿股骨长、头围、腹围增量均显著高于对照组;实验组胎龄（38±3）周,对照组（37±3）周;实验组出生体重（2750±378）g,对照组（2240±330）g;实验组胎盘质量（490±110）g,对照组（415±100）g.实验组并发症发生率明显低于对照组,上述比较项差异显著（P＜0.05）.结论 在进行治疗时要加强医患沟通,用药过程中密切观察患者表现、有无不良反应出现,早期进行健康教育,从而提高治疗效果.

Low molecular weight heparin in the treatment offetal growthrestriction and nursing intervention

Objective To study the clinical effects of Low molecular weight heparin in the treatment of fetal growth re- striction and related nursing interventions. Methods Choose 72 pregnant women with fetal growth restriction in our hos- pital from March 2010 to March 2012,they were treated with subcutaneous 5000U / d low molecular weight heparin, and select another 72 cases of fetal growth restriction pregnancy women the corresponding period who received basic treatment as a control group. Results After treatment ,mean uterine height increment and increments of fetal femur length, head circumference, abdominal circumference were significantly higher in experimental group than the control group;gestational age of experimental group was （38±3） weeks, the control group was （37e3） weeks; birth weight for experimental group was （2750±378） g, control group was （2240±330） g; placental weight of experimental group was （490 ± 110） g,white the control group was （415±100） g;the incidence of complications in experimental group was significantly lower than in control group.These items all had a significantly difference（P 〈0.05）. Conclusion Doctor-patient commu- nication should be strengthen during the course of treatment, closely observation of patients＇ performance during the treatment, whether or not occur adverse reactions, and early health education should be carried out at the earlier time, thereby enhancing the therapeutic effect.